ArticleFrontiers in public health2026
Baseline patient-reported symptom networks and early risk stratification for six-month symptom burden in newly diagnosed glioma: a prospective cohort study.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To characterize the baseline patient-reported symptom network in newly diagnosed glioma and to develop a baseline-only model for predicting high symptom burden at 6 months, with the aim of informing earlier symptom surveillance and risk-stratified supportive care. Methods: In a prospective cohort of 142 adults with histologically confirmed glioma, 15 patient-reported symptoms were rated at baseline using 0-10 numeric rating scales. Baseline symptom networks were estimated using Gaussian graphical modeling with graphical LASSO regularization and EBIC model selection. Edge accuracy and centrality stability were evaluated using nonparametric bootstrap and case-dropping procedures. High symptom burden at 6 months was defined using an upper-quartile rule based on the cohort distribution of the 6-month total symptom score. A random forest model incorporating baseline symptoms, clinical variables, and psychosocial factors was trained using a stratified split and internally validated in an independent test set. Results: The baseline network was moderately dense (38 edges; density = 0.36) and showed prominent cross-domain interdependencies. Speech difficulty and headache had the highest strength centrality, whereas betweenness and closeness showed lower stability. The random forest model achieved an AUC of 0.947 (95% CI, 0.888-1.000), and the leading predictors were baseline anxiety, depression, memory impairment, pain, fatigue, and age. Conclusion: Symptom burden in newly diagnosed glioma appears to arise from an interconnected patient-reported symptom pattern in which emotional, cognitive, physical, and neurological symptoms interact closely. Baseline multidimensional assessment and early risk stratification may help identify patients who warrant closer symptom surveillance and supportive care during the initial treatment course. These findings provide a basis for further external validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.